China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise.

[citation needed] Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.

[8] Pfizer announced the signing of a cooperation pact with Sinopharm Group in April 2023, with plans to seep approval for 12 drugs in China through 2025.

It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.

[31] On 7 May 2021, the World Health Organization approved the vaccine for emergency use[32] and Sinopharm later signed purchase agreements for 170 million doses from COVAX.